Study protocol: randomized phase III trial of neo-adjuvant and adjuvant chemotherapy vs. immediate surgery and adjuvant chemotherapy for localized soft tissue sarcoma: Japan Clinical Oncology Group study JCOG2102 (NACLESS)
Authors:
- Yuki FunauchiYFYuki Funauchi
- Satoshi TsukushiSTSatoshi Tsukushi
- Hiroaki HiragaHHHiroaki Hiraga
- Akio SakamotoASAkio Sakamoto
- Toshiyuki KunisadaTKToshiyuki Kunisada
- Akihito NaganoANAkihito Nagano
- Koji HiraokaKHKoji Hiraoka
- Kazutaka KikutaKazutaka Kikuta
- Tsukasa YonemotoTYTsukasa Yonemoto
- Keisuke AeKAKeisuke Ae
- Makoto EndoMakoto Endo
Open Access
- 5 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 55 (3) , 297-303
Abstract
The optimal timing of surgery and the number of courses of perioperative chemotherapy for high-risk soft tissue sarcoma patients are still controversial. Tumour growth during neoadjuvant chemotherapy led to limb amputation in some patients. This study aims to confirm the non-inferiority of surgery and three courses of adjuvant chemotherapy with adriamycin (30 mg/m2, days 1 and 2) plus ifosfamide (2 g/m2, days 1–5) compared with our standard treatment of three courses of neoadjuvant chemotherapy and surgery followed by two courses of adjuvant chemotherapy with adriamycin plus ifosfamide for localized high-risk soft tissue sarcoma patients. This is a multi-center, two-arm, open-label, randomized phase III trial. The primary aim is to confirm the non-inferiority in overall survival (margin: hazard ratio of 1.61). This is the first randomized controlled trial to compare neoadjuvant chemotherapy and immediate surgery for soft tissue sarcoma. This trial was initiated on 16 November 2022 and registered with the Japan Clinical Trials Registry (jRCTs031220446).Keywords
Funding Information
- National Cancer Center Research and Development Fund (2020-J-3, 2023-J-03)
This publication has 18 references indexed in Scilit:
- Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306British Journal of Cancer, 2022
- Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trialThe Lancet Oncology, 2017
- Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304)Japanese Journal of Clinical Oncology, 2015
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trialThe Lancet Oncology, 2012
- Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results databasePediatric Blood & Cancer, 2011
- A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcomaCancer, 2008
- A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcomaEuropean Journal of Cancer, 2001
- The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational settingSeminars in Radiation Oncology, 1999
- Prognostic variables for the selection of patients with operable soft tissue sarcomas to be considered in adjuvant chemotherapy trialsBritish Journal of Cancer, 1992